Brown Miller Wealth Management LLC Has $1.16 Million Stock Holdings in Johnson & Johnson $JNJ

Brown Miller Wealth Management LLC grew its position in Johnson & Johnson (NYSE:JNJ) by 1.2% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 7,595 shares of the company’s stock after buying an additional 92 shares during the period. Brown Miller Wealth Management LLC’s holdings in Johnson & Johnson were worth $1,160,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in JNJ. Highline Wealth Partners LLC raised its holdings in Johnson & Johnson by 51.8% during the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company’s stock worth $42,000 after buying an additional 86 shares during the period. Stone House Investment Management LLC bought a new stake in shares of Johnson & Johnson during the first quarter worth $47,000. 1248 Management LLC acquired a new stake in shares of Johnson & Johnson during the first quarter worth $48,000. von Borstel & Associates Inc. bought a new stake in Johnson & Johnson in the 1st quarter valued at $49,000. Finally, Harvest Fund Management Co. Ltd acquired a new position in Johnson & Johnson in the 1st quarter worth $52,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Stock Down 0.2%

NYSE:JNJ opened at $188.23 on Tuesday. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $189.92. The firm has a market capitalization of $453.32 billion, a price-to-earnings ratio of 20.13, a price-to-earnings-growth ratio of 2.40 and a beta of 0.40. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. The stock’s 50 day moving average price is $176.62 and its two-hundred day moving average price is $163.00.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, beating the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The business had revenue of $23.74 billion during the quarter, compared to analysts’ expectations of $22.85 billion. During the same period last year, the business earned $2.82 earnings per share. The firm’s revenue was up 5.8% on a year-over-year basis. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Equities research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were paid a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 2.8%. The ex-dividend date was Tuesday, August 26th. Johnson & Johnson’s dividend payout ratio (DPR) is 55.61%.

Analyst Ratings Changes

Several analysts have issued reports on JNJ shares. Morgan Stanley lifted their price target on Johnson & Johnson from $171.00 to $176.00 and gave the company an “equal weight” rating in a research note on Thursday, July 17th. Royal Bank Of Canada increased their price objective on Johnson & Johnson from $181.00 to $185.00 and gave the stock an “outperform” rating in a report on Thursday, July 17th. HSBC boosted their target price on Johnson & Johnson from $188.00 to $210.00 in a research note on Tuesday, September 30th. Piper Sandler reaffirmed an “overweight” rating on shares of Johnson & Johnson in a research note on Thursday, July 17th. Finally, Erste Group Bank raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Wednesday, July 23rd. Two investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $189.12.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the transaction, the executive vice president owned 178,013 shares of the company’s stock, valued at $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.